Shire completed the acquisition of Baxalta for $32bn.

Shire, a specialty biopharmaceutical company, completed the acquisition of Baxalta, a biopharmaceutical company, for $32bn. "Upon the completion of our combination with Baxalta, Shire is now the global leader in rare diseases, with the number one rare diseases platform based on both revenue and pipeline programs. With our multiple high-value franchises, each with best-in-class products and a robust innovative portfolio, we further extend our capabilities for innovation and sustainable growth with patients at the center of everything we do," Flemming Ornskov, Shire CEO.